Literature DB >> 9491836

Human maternofoetal distribution of pyrimethamine-sulphadoxine.

T Trenque, C Marx, C Quereux, B Leroux, D Dupouy, P H Dorangeon, H Choisy, J M Pinon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9491836      PMCID： PMC1873347          DOI： 10.1046/j.1365-2125.1998.00661.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  3 in total

1.  Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance.

Authors:  Whitney E Harrington; Theonest K Mutabingwa; Edward Kabyemela; Michal Fried; Patrick E Duffy
Journal:  Clin Infect Dis       Date:  2011-08-01       Impact factor: 9.079

Review 2.  Why prevent, diagnose and treat congenital toxoplasmosis?

Authors:  Rima McLeod; Francois Kieffer; Mari Sautter; Tiffany Hosten; Herve Pelloux
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

Review 3.  Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment.

Authors:  Philip J Peters; Michael C Thigpen; Monica E Parise; Robert D Newman
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.